Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study

BACKGROUND: Vedolizumab is a gut-selective anti-lymphocyte trafficking agent used to treat ulcerative colitis (UC) and Crohn’s disease. OBJECTIVES: We aimed to evaluate the effectiveness, safety, and durability of the therapeutic effect of vedolizumab after treatment discontinuation in a real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Eder, Piotr, Kłopocka, Maria, Cichoż-Lach, Halina, Talar-Wojnarowska, Renata, Kopertowska-Majchrzak, Maria, Michalak, Agata, Filip, Rafał, Waszak, Katarzyna, Stawczyk-Eder, Kamila, Janiak, Maria, Skrobot, Krzysztof, Liebert, Ariel, Zatorski, Hubert, Solarska-Półchłopek, Anna, Krogulecki, Michał, Pękała, Anna, Poniewierka, Elżbieta, Smoła, Izabela, Kaczka, Aleksandra, Wojciechowski, Krzysztof, Drygała, Szymon, Zagórowicz, Edyta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932778/
https://www.ncbi.nlm.nih.gov/pubmed/36818601
http://dx.doi.org/10.1177/17562848231151295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932778/
https://www.ncbi.nlm.nih.gov/pubmed/36818601
http://dx.doi.org/10.1177/17562848231151295

Ejemplares similares